$NCNA News

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe

NuCana Says European Patent Office Grants Patent Covering Composition Of Matter For NUC-7738

NuCana Has Been Granted European Patent Number EP3683225 Titled "NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS"

NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update

NuCana Appoints Ian Webster as Chief Financial Officer

NuCana Appoints Ian Webster CFO, Effective Immediately

NuCana Reports First Quarter 2026 Financial Results and Provides Business Update

NuCana shares are trading lower. The company reported Q4 financial results.

NuCana shares are trading lower. The company reported Q4 financial results.

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NuCana Q4 2025 EPS $0.00 and Revenue $0.00

European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

NuCana Appoints Theresa Bruce as Chief Operating Officer

NuCana Appoints Theresa Bruce COO, Effective Jan. 1

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

Nucana Reappoints Hugh S. Griffith As CEO, Effective Dec. 15

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma